Multiple sclerosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
{{CMG}} | {{CMG}} | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
Therapies under investigation: | |||
* Combination of MS drugs: Combination of [[mitoxantrone]] and [[glatiramer acetate]].<ref>[http://www.mxga-mstrial.co.uk United Kingdom early Mitoxantrone Copaxone trial.] Onyx Healthcare (2006-01-01). Retrieved on 2007-09-02.</ref> | |||
* drugs that are used in other diseases: [[alemtuzumab]]<ref>[http://www.genzyme.com/corp/media/GENZ%20PR-050207.asp Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN.] Genzyme (2007-02-01). Retrieved on 2007-09-02.</ref>, [[daclizumab]] <ref>[http://www.pdl.com/index.cfm?navId=49 Daclizumab.] PDL Biopharma (2006-01-01). Retrieved on 2007-09-02.</ref>, [[inosine]]<ref>[http://www.clinicaltrials.gov/ct/show/NCT00067327 Treatment of Multiple Sclerosis Using Over the Counter Inosine.] ClinicalTrials.gov (2006-03-16). Retrieved on 2007-09-02.</ref>, BG00012<ref>[http://www.clinicaltrials.gov/ct2/show/NCT00420212?term=biogen&recr=Open&rank=12 Efficacy and Safety of BG00012 in Relapsing-Remitting Multiple Sclerosis.] ClinicalTrials.gov (2007-09-01). Retrieved on 2007-11-12.</ref>, [[fingolimod]]<ref>[http://www.clinicaltrials.gov/ct/show/NCT00289978 Efficacy and Safety of Fingolimod in Patients With Relapsing-Remitting Multiple Sclerosis.] ClinicalTrials.gov (2006-02-09). Retrieved on 2007-09-02.</ref> and teriflunomide. | |||
* drugs designed specifically for MS: [[laquinimod]]<ref name="pmid15781813">{{cite journal |author=Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T |title=Treatment with laquinimod reduces development of active MRI lesions in relapsing MS |journal=Neurology |volume=64 |issue=6 |pages=987–91 |year=2005 |pmid=15781813|doi=10.1212/01.WNL.0000154520.48391.69}}</ref> and ''[[Neurovax]]''.<ref>{{cite journal |author=Darlington CL |title=Technology evaluation: NeuroVax, Immune Response Corp |journal=Curr. Opin. Mol. Ther. |volume=7 |issue=6 |pages=598–603 |year=2005|pmid=16370383 |doi=}}</ref> | |||
[[Low dose naltrexone]] | * Others: [[Low dose naltrexone]] is used for some [[autoimmune diseases]] such as multiple sclerosis.<ref>{{cite journal |author=Agrawal YP |title=Low dose naltrexone therapy in multiple sclerosis |journal=Med. Hypotheses |volume=64 |issue=4 |pages=721–4 |year=2005 |pmid=15694688 |doi=10.1016/j.mehy.2004.09.024|url=}}</ref><ref>[http://clinicaltrials.gov/ct2/results?term=Low+dose+naltrexone+Multiple+Sclerosis search of clinicaltrials.gov data-base for Low dose naltrexone Multiple Sclerosis]</ref> | ||
==References== | ==References== | ||
Revision as of 16:04, 4 March 2018
|
Multiple sclerosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Multiple sclerosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Multiple sclerosis future or investigational therapies |
|
FDA on Multiple sclerosis future or investigational therapies |
|
CDC on Multiple sclerosis future or investigational therapies |
|
Multiple sclerosis future or investigational therapies in the news |
|
Blogs on Multiple sclerosis future or investigational therapies |
|
Risk calculators and risk factors for Multiple sclerosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Future or Investigational Therapies
Therapies under investigation:
- Combination of MS drugs: Combination of mitoxantrone and glatiramer acetate.[1]
- drugs that are used in other diseases: alemtuzumab[2], daclizumab [3], inosine[4], BG00012[5], fingolimod[6] and teriflunomide.
- drugs designed specifically for MS: laquinimod[7] and Neurovax.[8]
- Others: Low dose naltrexone is used for some autoimmune diseases such as multiple sclerosis.[9][10]
References
- ↑ United Kingdom early Mitoxantrone Copaxone trial. Onyx Healthcare (2006-01-01). Retrieved on 2007-09-02.
- ↑ Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN. Genzyme (2007-02-01). Retrieved on 2007-09-02.
- ↑ Daclizumab. PDL Biopharma (2006-01-01). Retrieved on 2007-09-02.
- ↑ Treatment of Multiple Sclerosis Using Over the Counter Inosine. ClinicalTrials.gov (2006-03-16). Retrieved on 2007-09-02.
- ↑ Efficacy and Safety of BG00012 in Relapsing-Remitting Multiple Sclerosis. ClinicalTrials.gov (2007-09-01). Retrieved on 2007-11-12.
- ↑ Efficacy and Safety of Fingolimod in Patients With Relapsing-Remitting Multiple Sclerosis. ClinicalTrials.gov (2006-02-09). Retrieved on 2007-09-02.
- ↑ Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T (2005). "Treatment with laquinimod reduces development of active MRI lesions in relapsing MS". Neurology. 64 (6): 987–91. doi:10.1212/01.WNL.0000154520.48391.69. PMID 15781813.
- ↑ Darlington CL (2005). "Technology evaluation: NeuroVax, Immune Response Corp". Curr. Opin. Mol. Ther. 7 (6): 598–603. PMID 16370383.
- ↑ Agrawal YP (2005). "Low dose naltrexone therapy in multiple sclerosis". Med. Hypotheses. 64 (4): 721–4. doi:10.1016/j.mehy.2004.09.024. PMID 15694688.
- ↑ search of clinicaltrials.gov data-base for Low dose naltrexone Multiple Sclerosis